9 citations
,
April 2010 in “Lung cancer” This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.
22 citations
,
May 2011 in “European Journal of Cancer” This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.
22 citations
,
November 2005 in “BMC Cancer” This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.
May 2015 in “Cancer research” This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” This correspondence comments on the unknown prevalence of permanent alopecia following high-dose docetaxel chemotherapy and highlights the need for further understanding and prevention strategies.